Biochemical and Clinical Transitions Between the Hereditary Hepatic Porphyrias: New Concepts
Acute hepatic porphyrias are primarily molecular regulation diseases that are based on disturbances in porphyrin and heme biosynthesis (Fig. 1). Between the acute hepatic porphyrias — namely acute intermittent porphyria (AIP), porphyria variegata (PV), and hereditary coproporphyria (HCP) — there is an uninterrupted biochemical transition. Acute hepatic porphyrias have a series of common features, especially the sensitivity to lipid-soluble drugs, premenstrual manifestation, clinical syndrome with abdominal, cardiovascular, nervous and psychic symptoms, a similar constellation in the high urinary excretion of porphyrin precursors and porphyrins, and increased porphyrin excretion in feces in PV, in HCP, and in AIP. There is increased inducibility of 6-aminolevulinic acid (ALA) synthase in the Liver as a consequence of partial enzyme defects along the synthesis chain, of uroporphyrinogen synthase (uro-S) in AIP, of coproporphyrinogen oxidase in HCP, and probably of ferrochelatase or protoporphyrinogen oxidase in PV (Table 1). All respond to glucose, propranolol, and hematin therapy. They generally follow four phases: the phase of the genetic defect, the compensated and decompensated latent phase, and the clinical manifestation. From the clinical and biochemical point of view one can differentiate between a compensated and an uncompensated latent phase both in AIP and in PV (Table 2). AIP, PV, and HCP can appear with a syndrome clinically identical. In half of the cases of variegata we observed no skin symptoms.
KeywordsDepression Estrogen Hexa Chlorinate Porphyrin
Unable to display preview. Download preview PDF.
- 1.Doss, M.: Metabolism of δ-aminolevulinic acid and porphobilinogen in human erythrocytes in acute intermittent porphyria. In: Regulation of Porphyrins and Heme Biosynthesis. Doss, M. (ed.). Basel: Karger 1974, pp. 343–353Google Scholar
- 2.Doss, M., Schermuly, E.: Urinary porphyrin excretion pattern and isomer distribution of I and III in human porphyrin disorders. In: Porphyrins in Human Diseases. Doss, M. (ed.). Basel: Karger 1976, pp. 189–204.Google Scholar
- 3.Doss, M., Schermuly, E., Look, D., Henning, H., Hocevar, V,, Dohmen, K., Anlauf, M.: Studies on the metabolism of δ-aminolevulinic acid and porphobilinogen in liver biopsies from patients with acute intermittent porphyria. In: Porphyrins in Human Diseases. Doss, M. (ed.). Basel: Karger 1976, pp. 205–216Google Scholar
- 4.Doss, M., v. Tiepermann, R.: Uroporphyrinogen-Synthase in Erythrozyten bei akuter intermittierender Porphyrie (AIP): Neue pathobiochemische Aspekte. J. Clin. Chem. Clin. Biochem. (in press)Google Scholar
- 5.Strand, L.J., Felsher, B.F., Redéker, A.G., Marver, H.S.: Heme biosynthesis in intermittent acute porphyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta aminolevulinic acid synthase activity. Proceedings of the National Academy of Sciences. Vol. LXVII, No. 3, pp. 1315-1320Google Scholar
- 6.Wagner, G.S., Dinamarca, M.L., Tephly, T.R.: Studies on ferrochelatase activity: role in regulation of hepatic heme biosynthesis. In: Porphyrins in Human Diseases. Doss, M. (ed.). Basel: Karger 1976, pp. 111–122Google Scholar